Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-a*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation.

person Carlos Roberto Becerra Hoag Family Cancer Institute, Newport Beach, CA info_outline Carlos Roberto Becerra, Mark M. Awad, J. Randolph Hecht, Andrew Scott Paulson, Jennifer Lee, Gabi Palluconi, Jaquelin Dalton, Anuradha Patel, Ying Yan, Arianne Perez, Sunny Xie, Sarah Cohen, Marwan Fakih

Authors person Carlos Roberto Becerra Hoag Family Cancer Institute, Newport Beach, CA info_outline Carlos Roberto Becerra, Mark M. Awad, J. Randolph Hecht, Andrew Scott Paulson, Jennifer Lee, Gabi Palluconi, Jaquelin Dalton, Anuradha Patel, Ying Yan, Arianne Perez, Sunny Xie, Sarah Cohen, Marwan Fakih Organizations Hoag Family Cancer Institute, Newport Beach, CA, Lowe C, Dana-Farber Cancer Institute, Boston, MA, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Santa Monica, CA, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, Neogene Therapeutics, Inc. – An AstraZeneca Group company, Santa Monica, CA, Neogene, Santa Monica, CA, Neogene Therapeutics, Santa Monica, CA, Neogene Therapeutics, Inc., Santa Monica, CA, City of Hope Comprehensive Cancer Center, Duarte, CA Abstract Disclosures Research Funding Neogene Therapeutics, Inc. – An AstraZeneca Group company Background: The TP53 tumor suppressor gene is the most commonly mutated gene across all cancer types, and TP53 R175H is the most common recurrent mutation across indications, identified in 6.7% of patients with breast cancer, 6% of patients withs colorectal cancer, and 4.2% of patients with pancreatic cancer. No therapy is approved for treatment directly targeting TP53 R175H. NT-175 is an armored autologous T-cell product expressing an HLA-A*02:01-restricted TCR recognizing TP53 R175H with disruption of the endogenous TCR and the transforming growth factor beta receptor type 2 (TGFBR2) genes. Methods: This first-in-human phase I, open label study will assess the safety and preliminary anti-tumor activity, identify the maximum tolerated dose (MTD), and evaluate the persistence, and functional capacity of NT-175 in subjects with advanced, recurrent unresectable/metastatic solid tumors refractory to treatment options. The study will enroll approximately 24 subjects harboring TP53 R175H and HLA-A*02:01. Enrolled patients will undergo leukapheresis from which CD4 and CD8 T cells will be enriched and activated ex vivo. The endogenous TCR α and β chain gene are knocked out utilizing clustered Regularly Interspaced Short Palindromic repeats (CRISPR-Cas9) and the TCR encoding an HLA-A*02:01-restricted TCR specific to the TP53 R175H mutation is inserted in the TCR α locus. Additionally, the T cells are edited to disrupt the gene encoding the TGFBR2 to reduce the immunosuppressive effect of TGF-β in the tumor microenvironment. Subjects will undergo lymphodepletion chemotherapy with fludarabine and cyclophosphamide followed by a single infusion of NT-175 and subcutaneous recombinant IL-2 administration for up to 8 days. Dose escalation will occur across 3 ascending dose levels following the BOIN design. Subjects will be monitored for dose-limiting toxicities for 28 days after NT-175 infusion. Tumor response will be assessed by RECISTv1.1 criteria. All subjects will be followed for up to 15 years. Primary endpoints include safety, dose limited toxicities, MTD determination, and recommended Phase II dose. Secondary endpoints include preliminary efficacy measures. Translational analysis will evaluate potential biomarkers for insights into mechanism of action, response prediction, or resistance mechanisms. The study was activated in March 2023 and is open to accrual; 5 patients have been enrolled as of 4 Jan 2024.